Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder
January 22, 2016 9:40 AM EST
UBS maintained a Neutral rating on Alkermes (NASDAQ: ALKS), and cut the price target to $36.00 (from $65.00). With the failure of FORWARD-3 and FORWARD-4 studies for ALKS 5461 in MDD, UBS believes that there is a very low possibility of getting this product approved even... More
January 21, 2016 12:52 PM EST
Morgan Stanley downgraded Alkermes (NASDAQ: ALKS) from Overweight to Underweight with a price target of $35.00.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
...
More
January 21, 2016 10:07 AM EST
Leerink Partners analyst Paul Matteis lowered his price target on Alkermes (NASDAQ: ALKS) to $58.00 (from $84.00) after the company released news on two of its Phase 3 programs for ALKS5461 missing their primary endpoints (PEs). The firm maintained an Outperform rating.
Matteis commented, ". While the... More
January 21, 2016 9:51 AM EST
Cowen downgraded Alkermes (NASDAQ: ALKS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
...
More
